BIOFRONTERA AG NA O.N. overview

DGAP-News: Biofrontera AG / Key word(s): Annual Results Biofrontera AG: Biofrontera Reports Full Year 2019 Financial Results 20.04.2020 / 17:00 The issuer is solely responsible for the content of this announcement. Biofrontera Reports Full Year 2019 Financial Results Leverkusen, Germany, April 20, 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today reported its financial results for the full year ended December...

DGAP-Ad-hoc: Biofrontera AG / Key word(s): Contract Biofrontera AG: Biofrontera AG enters into exclusive license agreement with Maruho Co., Ltd. 20-Apr-2020 / 10:19 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad-hoc Release pursuant to Art. 17 MAR Biofrontera AG enters into exclusive license agreement with Maruho Co.,...

DGAP-News: Biofrontera AG / Key word(s): Preliminary Results/Development of Sales Biofrontera AG: Biofrontera reports preliminary unaudited sales revenue for the first three months of 2020 17.04.2020 / 11:15 The issuer is solely responsible for the content of this announcement. Biofrontera reports preliminary unaudited sales revenue for the first three months of 2020 Leverkusen, Germany, April 17, 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an...

DGAP-Ad-hoc: Biofrontera AG / Key word(s): Capital Increase Biofrontera AG: Biofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting 16-Apr-2020 / 16:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad-hoc Release pursuant to Art. 17 MAR Biofrontera AG to propose resolution for...

DGAP-News: Biofrontera AG / Key word(s): Miscellaneous Biofrontera AG: 09.04.2020 / 18:30 The issuer is solely responsible for the content of this announcement. Biofrontera announces conference call to be held on April 21, 2020 to discuss full year 2019 financial results Leverkusen, Germany, April 9, 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the full year 2019 on...

DGAP-Ad-hoc: Biofrontera AG / Key word(s): Corporate Action Biofrontera AG: Biofrontera AG withdraws subscription offers for mandatory convertible bonds 23-March-2020 / 15:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad-hoc Release pursuant to Art. 17 MAR Biofrontera AG withdraws subscription offers for mandatory...

DGAP-News: Biofrontera AG / Key word(s): Miscellaneous Biofrontera AG: Biofrontera implements comprehensive measures to reduce costs during COVID-19 pandemic 20.03.2020 / 09:15 The issuer is solely responsible for the content of this announcement. Biofrontera implements comprehensive measures to reduce costs during COVID-19 pandemic Leverkusen, Germany, March 20, 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company,...

DGAP-Ad-hoc: Biofrontera AG / Key word(s): Miscellaneous Biofrontera AG: Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz(R) in Poland with medac GmbH Sp. z o.o. 13-March-2020 / 13:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad-hoc Release pursuant to Art. 17 MAR Biofrontera AG signs...